Novavax (NVAX) Shares Outstanding (2010 - 2026)

Novavax's Shares Outstanding (Entity) history runs 17 years deep, the most recent figure standing at $167.8 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Entity) rose 2.17% year-over-year to $167.8 million; the TTM figure through Mar 2026 stood at $167.8 million (up 2.17% YoY), while the FY2025 annual figure was $165.0 million, up 1.87% from the prior year.
• Shares Outstanding (Entity) for Q1 2026 stood at $167.8 million, up from $165.0 million in the prior quarter.
• The five-year high for Shares Outstanding (Entity) was $167.8 million in Q1 2026, with the low at $78.7 million in Q1 2022.
• The 5-year median for Shares Outstanding (Entity) is $141.7 million (2024), against an average of $128.2 million.
• The sharpest annual moves came in 2024 and 2025: Shares Outstanding (Entity) surged 69.43% in 2024, then increased 1.87% in 2025.
• Novavax's Shares Outstanding (Entity) stood at $86.8 million in 2022, then increased by 16.08% to $100.8 million in 2023, then jumped by 60.71% to $161.9 million in 2024, then climbed by 1.87% to $165.0 million in 2025, then rose by 1.69% to $167.8 million in 2026.
• Business Quant data shows NVAX's Shares Outstanding (Entity) at $167.8 million in Q1 2026, $165.0 million in Q4 2025, and $164.8 million in Q3 2025.